Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover Meeting Abstract

sustainable development goals

publication date

  • February 1, 2016

webpage

published in

volume

  • 34

issue

  • 4